HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Target Cruises Past Hypoallergenic Cosmetic Suit, But Other Defendants On Rockier Road

This article was originally published in The Rose Sheet

Executive Summary

The plaintiff in a proposed class action against Target Corporation for alleged “hypoallergenic” cosmetic fraud neglected to venture a definition for the term and focused to a distracting extent on claims ultimately found to be non-actionable puffery – e.g., “gentle.” Other hypoallergic suits pending around the US are built on sturdier ground and likely will be harder to dismiss.

You may also be interested in...



European Guidelines Now In Effect For ‘Free From,’ ‘Hypoallergenic’ Cosmetic Claims

According to Cosmetics Europe, at least “several” EU Member States are expected to be monitoring the marketplace for compliance with guidance developed by a European Commission working group, key aspects of which – concerning “free from” and “hypoallergenic” claims – went into effect 1 July.

California’s SB 1249 Could Plant Seeds For New Plaintiff Cottage Industry

The Cruelty-Free Cosmetics Act, passed Aug. 31, conceivably could give rise to consumer suits alleging violation of California’s Unfair Competition Law due to companies’ alleged use of prohibited animal testing to develop cosmetic products or substantiate their safety. Regardless, claiming exemptions under SB 1249 promises to be risky business with limited rewards.

Plaintiff Digs Deep In Almay Archives For ‘Hypoallergic’ Fraud Evidence

In the absence of FDA regulations, federal courts generally are weighing hypoallergenic false-advertising arguments against the “reasonable consumer” standard, with varying results. However, Almay may have provided a more substantive basis for assessing the truthfulness of its hypoallergenic claims via a letter to FDA on the subject – albeit one from 1973.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS121782

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel